Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

SkyCity - Lack of One Sale Leads to Another

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Skycity Entertainment / Equity Capital Markets

<p>SkyCity launched an NZD 180 million institutional placement and an NZD 50 million share purchase plan this morning. In this note, we will take a look at the details of the capital raising and provide our thoughts on the deal. Although the stock has not gone anywhere in the past five years, we do think that the placement provides an interesting opportunity to profit from both business recovery and performance catch-up with peers.</p>

SkyCity launched an NZD 180 million institutional placement and an NZD 50 million share purchase plan this morning. In this note, we will take a look at the details of the capital raising and provide our thoughts on the deal. Although the stock has not gone anywhere in the past five years, we do think that the placement provides an interesting opportunity to profit from both business recovery and performance catch-up with peers.

SkyCity Placement: Past Performance and the Relative Value Trade